MaxCyte (MXCT)
(Delayed Data from NSDQ)
$4.49 USD
+0.03 (0.67%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $4.52 +0.03 (0.67%) 7:58 PM ET
1-Strong Buy of 5 1
F Value D Growth F Momentum F VGM
MaxCyte, Inc. (MXCT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$9.25 | $11.00 | $7.00 | 107.40% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for MaxCyte, Inc. comes to $9.25. The forecasts range from a low of $7.00 to a high of $11.00. The average price target represents an increase of 107.4% from the last closing price of $4.46.
Analyst Price Targets (4 )
Broker Rating
MaxCyte, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, six are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 6 | 6 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/1/2024 | Cowen & Co. | Steven Mah | Strong Buy | Strong Buy |
3/13/2024 | BTIG | Mark Massaro | Strong Buy | Strong Buy |
3/13/2024 | Stephens | Jacob Johnson | Strong Buy | Strong Buy |
3/5/2024 | William Blair | Matt Larew | Strong Buy | Strong Buy |
11/29/2023 | Craig-Hallum | Matthew G Hewitt | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 6 |
Average Target Price | $9.25 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 75 of 252 |
Current Quarter EPS Est: | -0.14 |